GeneDx (WGSWW) Financials

$0.13 +0.03 (+28.00%)

As of 04:00 PM Eastern

Annual Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-33	-241	-245	-549	-176	-52
Consolidated Net Income / (Loss)	-30	-241	-245	-549	-176	-52
Net Income / (Loss) Continuing Operations	-30	-241	-245	-549	-176	-52
Total Pre-Tax Income	-30	-241	-245	-598	-177	-53
Total Operating Income	-30	-242	-446	-668	-181	-23
Total Gross Profit	83	4.03	-17	-27	90	194
Total Revenue	196	179	212	235	203	305
Operating Revenue	196	179	212	235	203	305
Total Cost of Revenue	113	175	229	261	113	111
Operating Cost of Revenue	113	175	229	261	113	111
Total Operating Expenses	113	246	430	641	271	218
Selling, General & Admin Expense	29	101	206	216	134	101
Marketing Expense	39	63	113	122	61	67
Research & Development Expense	35	73	105	86	58	46
Other Operating Expenses / (Income)	9.45	9.40	5.66	6.31	7.22	3.41
Impairment Charge	-	0.00	0.00	210	10	0.00
Total Other Income / (Expense), net	0.71	0.65	201	70	2.73	-29
Interest & Investment Income	0.99	0.51	0.08	-	1.11	-3.03
Other Income / (Expense), net	0.50	2.62	204	70	1.62	-26
Income Tax Expense	0.00	0.00	0.00	-49	-0.93	-0.34
Basic Earnings per Share	($264,056.00)	($47,036.00)	($2.27)	($53.63)	($7.23)	($1.94)
Weighted Average Basic Shares Outstanding	124.00	5.13K	108.08M	10.24M	24.31M	26.89M
Diluted Earnings per Share	($264,056.00)	($47,036.00)	($2.27)	($53.63)	($7.23)	($1.94)
Weighted Average Diluted Shares Outstanding	124.00	5.13K	108.08M	10.24M	24.31M	26.89M
Weighted Average Basic & Diluted Shares Outstanding	-	-	244.96M	798.25M	26.05M	28.07M

This table shows GeneDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-78	-309	-61	-47	-42	-26	-20	-29	-8.31	5.44	-6.53
Consolidated Net Income / (Loss)	-78	-309	-61	-47	-42	-26	-20	-29	-8.31	5.44	-6.53
Net Income / (Loss) Continuing Operations	-78	-309	-61	-47	-42	-26	-20	-29	-8.31	5.44	-6.53
Total Pre-Tax Income	-78	-309	-61	-47	-42	-26	-20	-29	-8.36	5.41	-6.08
Total Operating Income	-91	-325	-60	-52	-43	-26	-14	-11	-7.78	8.81	-4.55
Total Gross Profit	14	-16	15	19	25	31	37	43	48	66	58
Total Revenue	83	61	43	49	53	57	62	71	77	96	87
Operating Revenue	83	61	43	49	53	57	62	71	77	96	87
Total Cost of Revenue	70	78	28	30	28	27	25	28	29	29	29
Operating Cost of Revenue	70	78	28	30	28	27	25	28	29	29	29
Total Operating Expenses	104	309	76	70	68	56	51	54	56	57	63
Selling, General & Admin Expense	55	43	44	37	26	27	22	25	26	27	32
Marketing Expense	34	29	13	15	17	16	16	17	17	18	18
Research & Development Expense	13	24	15	17	14	12	12	11	12	12	13
Total Other Income / (Expense), net	13	16	-0.77	4.71	0.51	-1.71	-6.66	-19	-0.58	-3.39	-1.53
Interest & Investment Income	-	-	-	1.07	1.05	-	-	-0.89	-0.84	-	-0.64
Other Income / (Expense), net	13	16	-0.74	3.63	-0.54	-0.73	-6.06	-18	0.26	-2.69	-0.89
Income Tax Expense	-0.07	0.09	-0.15	-0.20	-0.17	-0.41	-0.08	-0.19	-0.05	-0.02	0.45
Basic Earnings per Share	($6.72)	($30.16)	($3.04)	($1.84)	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)
Weighted Average Basic Shares Outstanding	11.54M	10.24M	20.06M	25.42M	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M
Diluted Earnings per Share	($6.72)	($30.16)	($3.04)	($1.84)	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)
Weighted Average Diluted Shares Outstanding	11.54M	10.24M	20.06M	25.42M	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M
Weighted Average Basic & Diluted Shares Outstanding	386.80M	798.25M	25.59M	25.77M	25.88M	26.05M	26.14M	26.94M	27.47M	28.07M	28.53M

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	114	3.95	283	-263	-38	-14
Net Cash From Operating Activities	-19	-93	-190	-319	-180	-28
Net Cash From Continuing Operating Activities	-19	-93	-192	-319	-180	-29
Net Income / (Loss) Continuing Operations	-30	-241	-245	-549	-176	-52
Consolidated Net Income / (Loss)	-30	-241	-245	-549	-176	-52
Depreciation Expense	6.41	12	22	59	34	22
Non-Cash Adjustments To Reconcile Net Income	6.73	123	25	183	-1.35	23
Changes in Operating Assets and Liabilities, net	-2.16	14	6.65	-13	-37	-21
Net Cash From Investing Activities	-15	-32	-21	-141	-44	-30
Net Cash From Continuing Investing Activities	-15	-32	-21	-141	-44	-30
Purchase of Property, Plant & Equipment	-15	-32	-21	-14	-5.71	-5.49
Acquisitions	-	0.00	0.00	-127	-12	0.00
Purchase of Investments	-	-	-	0.00	-48	-66
Sale of Property, Plant & Equipment	-	-	-	0.00	4.03	0.00
Sale and/or Maturity of Investments	-	-	-	0.00	18	42
Net Cash From Financing Activities	148	129	494	197	186	44
Net Cash From Continuing Financing Activities	148	129	498	197	186	44
Repayment of Debt	-1.71	-0.19	-10	0.00	-2.00	-0.50
Issuance of Debt	0.00	16	0.00	0.00	49	0.00
Issuance of Common Equity	0.00	0.00	793	198	143	47
Other Financing Activities, net	31	-4.01	-2.46	-0.34	-3.31	-2.33
Cash Interest Paid	0.31	1.75	2.75	1.93	3.04	6.68
Cash Income Taxes Paid	0.00	0.00	0.35	1.24	1.47	1.17

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-93	-67	77	-57	-69	12	-16	-28	1.82	27	14
Net Cash From Operating Activities	-88	-65	-56	-54	-41	-30	-16	-4.51	-4.40	-3.18	10
Net Cash From Continuing Operating Activities	-88	-65	-56	-54	-41	-30	-16	-4.51	-4.40	-3.45	10
Net Income / (Loss) Continuing Operations	-78	-309	-61	-47	-42	-26	-20	-29	-8.31	5.44	-6.53
Consolidated Net Income / (Loss)	-78	-309	-61	-47	-42	-26	-20	-29	-8.31	5.44	-6.53
Depreciation Expense	11	34	8.64	10	8.67	6.09	5.25	5.22	5.93	5.56	5.68
Non-Cash Adjustments To Reconcile Net Income	-8.74	194	1.80	-7.01	6.60	-2.74	5.50	22	2.89	-7.99	6.48
Changes in Operating Assets and Liabilities, net	-13	16	-5.01	-10	-14	-7.44	-6.92	-2.85	-4.90	-6.45	4.56
Net Cash From Investing Activities	-4.28	-2.84	-0.46	-11	-27	-4.86	0.84	-23	-7.76	-0.52	-9.41
Net Cash From Continuing Investing Activities	-4.28	-2.84	-0.46	-11	-27	-4.86	0.84	-23	-7.76	-0.52	-9.41
Purchase of Property, Plant & Equipment	-4.28	-2.84	-0.46	-2.76	-0.11	-2.38	-0.44	-1.35	-0.65	-3.05	-6.13
Purchase of Investments	-	-	0.00	-	-44	-3.74	-5.17	-24	-23	-14	-17
Sale and/or Maturity of Investments	-	-	0.00	-	17	1.10	6.45	2.87	16	16	14
Net Cash From Financing Activities	-0.65	0.07	133	7.39	-0.91	47	-0.44	-0.39	14	31	14
Net Cash From Continuing Financing Activities	-0.65	0.07	133	7.39	-0.91	47	-0.44	-0.39	14	31	14
Repayment of Debt	-	-	-2.00	-	-	-	0.00	-	-0.20	-0.30	-0.30
Issuance of Common Equity	-0.05	-	135	7.56	-	-	0.00	-	15	32	14
Other Financing Activities, net	-0.59	0.07	-0.78	-0.18	-0.91	-1.45	-0.44	-0.39	-0.42	-1.08	0.12
Cash Interest Paid	0.60	0.14	0.58	0.36	0.17	1.93	2.02	2.01	2.04	0.61	1.60
Cash Income Taxes Paid	0.12	0.75	0.10	0.90	0.18	0.29	0.30	0.26	0.35	0.26	0.21

This table presents GeneDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	252	554	491	419	419
Total Current Assets	174	484	213	182	198
Cash & Equivalents	108	401	124	100	85
Short-Term Investments	-	-	0.00	30	56
Accounts Receivable	32	27	43	33	38
Inventories, net	25	33	14	8.78	11
Prepaid Expenses	4.56	19	32	11	8.50
Plant, Property, & Equipment, net	63	63	52	32	33
Total Noncurrent Assets	14	7.83	227	204	189
Intangible Assets	-	0.00	187	173	159
Other Noncurrent Operating Assets	14	7.83	40	31	30
Total Liabilities & Shareholders' Equity	252	554	491	419	419
Total Liabilities	247	166	237	191	174
Total Current Liabilities	73	101	144	59	55
Accounts Payable	28	47	85	37	30
Other Current Liabilities	30	34	59	21	25
Total Noncurrent Liabilities	174	65	93	132	119
Long-Term Debt	19	11	6.25	53	52
Capital Lease Obligations	21	0.00	60	63	61
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.00	2.66	1.56	0.97
Other Noncurrent Operating Liabilities	2.07	54	24	15	5.52
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-330	388	254	228	245
Total Preferred & Common Equity	-330	388	254	228	245
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-330	388	254	228	245
Common Stock	0.00	964	1,378	1,528	1,597
Retained Earnings	-330	-575	-1,124	-1,300	-1,352
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	0.43	0.83

This table presents GeneDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	829	545	476	417	395	389	409	446
Total Current Assets	307	272	213	172	163	162	186	226
Cash & Equivalents	191	202	157	87	84	56	58	100
Short-Term Investments	-	-	-	27	29	51	59	59
Accounts Receivable	44	34	34	32	29	26	38	46
Inventories, net	44	12	12	9.35	12	10	11	13
Prepaid Expenses	18	12	11	16	9.97	19	20	8.01
Plant, Property, & Equipment, net	84	50	43	36	31	31	31	36
Total Noncurrent Assets	438	223	220	210	200	196	191	184
Intangible Assets	190	183	180	176	169	166	162	155
Other Noncurrent Operating Assets	66	40	40	34	31	30	29	29
Total Liabilities & Shareholders' Equity	829	545	476	417	395	389	409	446
Total Liabilities	268	217	180	163	187	195	204	189
Total Current Liabilities	162	119	84	68	51	68	77	70
Accounts Payable	89	74	55	39	32	52	56	42
Other Current Liabilities	74	45	30	29	18	16	21	28
Total Noncurrent Liabilities	105	98	96	95	137	127	127	119
Long-Term Debt	11	6.25	6.25	6.05	52	52	52	52
Capital Lease Obligations	62	64	64	64	62	61	60	60
Noncurrent Deferred & Payable Income Tax Liabilities	2.60	2.51	2.25	2.06	1.42	1.17	1.05	1.15
Other Noncurrent Operating Liabilities	30	25	24	23	21	13	14	6.62
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	561	328	296	254	207	194	205	257
Total Preferred & Common Equity	561	328	296	254	207	194	205	257
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	561	328	296	254	207	194	205	257
Common Stock	1,377	1,514	1,528	1,529	1,527	1,543	1,561	1,616
Retained Earnings	-816	-1,185	-1,232	-1,274	-1,320	-1,350	-1,358	-1,359
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	0.29	0.46	0.92	0.91

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	-8.59%	18.33%	10.60%	-13.69%	50.79%
EBITDA Growth	0.00%	-868.59%	3.02%	-143.73%	73.01%	80.97%
EBIT Growth	0.00%	-700.33%	-1.36%	-146.20%	70.04%	72.29%
NOPAT Growth	0.00%	-695.69%	-84.36%	-49.65%	72.95%	87.15%
Net Income Growth	0.00%	-712.48%	-1.68%	-123.72%	67.98%	70.25%
EPS Growth	0.00%	82.19%	100.00%	-123.72%	86.52%	73.17%
Operating Cash Flow Growth	0.00%	-397.27%	-104.49%	-67.59%	43.56%	84.18%
Free Cash Flow Firm Growth	0.00%	0.00%	-240.96%	-79.05%	78.36%	86.34%
Invested Capital Growth	0.00%	0.00%	97.58%	13,472.10%	8.91%	1.59%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	1.54%	-1.90%	14.30%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-81.56%	63.68%	52.69%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-82.20%	61.23%	38.70%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-45.60%	62.36%	59.74%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-95.78%	61.69%	37.38%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-95.78%	59.36%	37.01%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-21.46%	-4.13%	16.19%	48.35%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-39.87%	36.43%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-55.74%	1.71%	8.21%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	42.20%	2.25%	-7.82%	-11.40%	44.43%	63.64%
EBITDA Margin	-11.98%	-126.94%	-104.04%	-229.26%	-71.70%	-9.05%
Operating Margin	-15.50%	-134.95%	-210.25%	-284.48%	-89.15%	-7.60%
EBIT Margin	-15.25%	-133.49%	-114.34%	-254.53%	-88.35%	-16.24%
Profit (Net Income) Margin	-15.14%	-134.58%	-115.64%	-233.91%	-86.77%	-17.12%
Tax Burden Percent	100.00%	100.00%	100.00%	91.80%	99.48%	99.35%
Interest Burden Percent	99.31%	100.82%	101.14%	100.11%	98.72%	106.11%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-480.40%	-61.74%	-7.55%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-443.90%	74.98%	160.55%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	309.33%	-11.24%	-14.55%
Return on Equity (ROE)	0.00%	-5,500.00%	-125.04%	-171.07%	-72.97%	-22.10%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-339.15%	-70.26%	-9.13%
Operating Return on Assets (OROA)	0.00%	-95.12%	-60.23%	-114.32%	-39.35%	-11.84%
Return on Assets (ROA)	0.00%	-95.91%	-60.91%	-105.06%	-38.64%	-12.48%
Return on Common Equity (ROCE)	0.00%	413,692.00%	-18.49%	-171.07%	-72.97%	-22.10%
Return on Equity Simple (ROE_SIMPLE)	0.00%	73.12%	-63.23%	-216.39%	-77.09%	-21.32%
Net Operating Profit after Tax (NOPAT)	-21	-169	-312	-467	-126	-16
NOPAT Margin	-10.85%	-94.46%	-147.18%	-199.13%	-62.41%	-5.32%
Net Nonoperating Expense Percent (NNEP)	0.00%	-221.79%	29.45%	-36.50%	-136.72%	-168.10%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-36.79%	-4.54%
Cost of Revenue to Revenue	57.80%	97.75%	107.82%	111.40%	55.57%	36.36%
SG&A Expenses to Revenue	15.03%	56.18%	97.07%	92.11%	66.03%	33.10%
R&D to Revenue	17.80%	40.54%	49.56%	36.73%	28.76%	14.97%
Operating Expenses to Revenue	57.70%	137.19%	202.43%	273.08%	133.59%	71.24%
Earnings before Interest and Taxes (EBIT)	-30	-239	-243	-597	-179	-50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-24	-228	-221	-538	-145	-28
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	2.77	0.40	0.31	8.61
Price to Tangible Book Value (P/TBV)	0.00	0.00	2.77	1.52	1.29	24.37
Price to Revenue (P/Rev)	1.96	3.41	5.07	0.43	0.35	6.91
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.23	0.27	9.60
Enterprise Value to Revenue (EV/Rev)	0.00	4.91	3.24	0.19	0.28	6.82
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	9.86	0.03	0.26	0.51	0.46
Long-Term Debt to Equity	0.00	9.06	0.03	0.26	0.51	0.46
Financial Leverage	0.00	-14.79	-1.16	-0.70	-0.15	-0.09
Leverage Ratio	0.00	57.35	2.05	1.63	1.89	1.77
Compound Leverage Factor	0.00	57.82	2.08	1.63	1.86	1.88
Debt to Total Capital	0.00%	90.79%	2.76%	20.71%	33.65%	31.51%
Short-Term Debt to Total Capital	0.00%	7.36%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	83.43%	2.76%	20.71%	33.65%	31.51%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	701.97%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-692.76%	97.24%	79.29%	66.35%	68.49%
Debt to EBITDA	0.00	-0.19	-0.05	-0.12	-0.80	-4.08
Net Debt to EBITDA	0.00	0.29	1.76	0.11	0.10	1.03
Long-Term Debt to EBITDA	0.00	-0.17	-0.05	-0.12	-0.80	-4.08
Debt to NOPAT	0.00	-0.26	-0.04	-0.14	-0.91	-6.94
Net Debt to NOPAT	0.00	0.38	1.25	0.12	0.11	1.74
Long-Term Debt to NOPAT	0.00	-0.23	-0.04	-0.14	-0.91	-6.94
Altman Z-Score	0.00	-2.30	2.20	-6.32	-4.70	3.51
Noncontrolling Interest Sharing Ratio	0.00%	7,621.67%	85.21%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	2.37	4.77	1.47	3.10	3.61
Quick Ratio	0.00	1.91	4.22	1.16	2.77	3.26
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-109	-371	-665	-144	-20
Operating Cash Flow to CapEx	-121.17%	-291.26%	-916.16%	-2,228.42%	-10,742.22%	-518.96%
Free Cash Flow to Firm to Interest Expense	0.00	-44.02	-130.98	-998.28	0.00	0.00
Operating Cash Flow to Interest Expense	-23.92	-37.64	-67.17	-479.21	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-43.66	-50.57	-74.50	-500.72	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.71	0.53	0.45	0.45	0.73
Accounts Receivable Turnover	0.00	5.55	7.21	6.71	5.32	8.67
Inventory Turnover	0.00	7.02	7.83	11.10	10.03	11.43
Fixed Asset Turnover	0.00	2.84	3.37	4.11	4.82	9.35
Accounts Payable Turnover	0.00	6.22	6.06	3.96	1.84	3.29
Days Sales Outstanding (DSO)	0.00	65.81	50.65	54.36	68.61	42.09
Days Inventory Outstanding (DIO)	0.00	51.98	46.60	32.89	36.39	31.93
Days Payable Outstanding (DPO)	0.00	58.64	60.21	92.28	198.35	110.93
Cash Conversion Cycle (CCC)	0.00	59.15	37.05	-5.03	-93.35	-36.91
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	-60	-1.47	196	213	217
Invested Capital Turnover	0.00	-5.93	-6.85	2.41	0.99	1.42
Increase / (Decrease) in Invested Capital	0.00	-60	59	198	17	3.40
Enterprise Value (EV)	0.00	881	686	44	57	2,083
Market Capitalization	385	611	1,076	102	71	2,111
Book Value per Share	$0.00	($5.96)	$1.61	$0.66	$8.81	$8.93
Tangible Book Value per Share	$0.00	($5.96)	$1.61	$0.17	$2.14	$3.15
Total Capital	0.00	48	399	320	344	358
Total Debt	0.00	43	11	66	116	113
Total Long-Term Debt	0.00	40	11	66	116	113
Net Debt	0.00	-65	-390	-58	-15	-28
Capital Expenditures (CapEx)	15	32	21	14	1.68	5.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-3.96	-18	-56	-6.63	1.97
Debt-free Net Working Capital (DFNWC)	0.00	104	382	68	124	143
Net Working Capital (NWC)	0.00	101	382	68	124	143
Net Nonoperating Expense (NNE)	8.41	72	-67	82	49	36
Net Nonoperating Obligations (NNO)	0.00	-65	-390	-58	-15	-28
Total Depreciation and Amortization (D&A)	6.41	12	22	59	34	22
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-2.21%	-8.63%	-23.69%	-3.27%	0.64%
Debt-free Net Working Capital to Revenue	0.00%	58.09%	180.15%	29.11%	60.98%	46.87%
Net Working Capital to Revenue	0.00%	56.14%	180.15%	29.11%	60.98%	46.87%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($53.79)	($7.23)	($1.94)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	10.24M	24.31M	26.89M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($53.79)	($7.23)	($1.94)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	10.24M	24.31M	26.89M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	24.19M	26.05M	28.07M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-169	-312	-320	-119	-16
Normalized NOPAT Margin	-10.85%	-94.46%	-147.18%	-136.46%	-58.81%	-5.32%
Pre Tax Income Margin	-15.14%	-134.58%	-115.64%	-254.81%	-87.23%	-17.23%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-38.20	-96.76	-85.59	-896.95	0.00	0.00
NOPAT to Interest Expense	-27.19	-68.47	-110.16	-701.74	0.00	0.00
EBIT Less CapEx to Interest Expense	-57.94	-109.68	-92.92	-918.45	0.00	0.00
NOPAT Less CapEx to Interest Expense	-46.93	-81.39	-117.49	-723.24	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	-21.09%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-21.09%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	92.77%	6.14%	-20.03%	34.66%	-35.96%	-6.41%	44.70%	44.77%	44.22%	66.57%	39.56%
EBITDA Growth	-272.86%	-717.40%	25.25%	69.95%	48.16%	92.62%	72.41%	38.26%	95.44%	157.54%	101.63%
EBIT Growth	-333.13%	-682.29%	19.73%	64.30%	44.10%	91.46%	67.72%	40.68%	82.73%	123.17%	72.41%
NOPAT Growth	27.98%	-180.60%	32.41%	68.26%	52.69%	92.11%	77.37%	79.51%	81.89%	149.28%	66.68%
Net Income Growth	-337.03%	-668.35%	20.69%	45.51%	45.49%	91.65%	66.82%	37.56%	80.34%	121.10%	67.74%
EPS Growth	-337.03%	-668.35%	20.69%	78.04%	75.60%	96.49%	74.34%	40.22%	81.10%	118.87%	70.51%
Operating Cash Flow Growth	-24.56%	-24.37%	31.82%	36.79%	53.34%	53.82%	70.46%	91.58%	89.34%	89.34%	162.04%
Free Cash Flow Firm Growth	-241.98%	0.00%	-193.63%	179.42%	135.89%	91.67%	76.63%	-98.95%	-98.02%	115.38%	86.57%
Invested Capital Growth	850.55%	13,472.10%	122.58%	-50.88%	-52.61%	8.91%	13.04%	-4.45%	-4.51%	1.59%	0.64%
Revenue Q/Q Growth	130.13%	-26.29%	-29.68%	12.90%	9.44%	7.72%	8.72%	12.96%	9.02%	24.41%	-8.91%
EBITDA Q/Q Growth	46.37%	-309.15%	80.92%	28.22%	7.48%	41.78%	24.26%	-60.62%	93.17%	835.35%	-97.98%
EBIT Q/Q Growth	42.09%	-296.99%	80.23%	21.46%	9.33%	39.38%	21.75%	-44.34%	73.60%	181.32%	-189.04%
NOPAT Q/Q Growth	44.16%	-257.74%	81.42%	14.48%	16.77%	40.32%	46.73%	22.55%	26.46%	262.41%	-136.02%
Net Income Q/Q Growth	9.52%	-297.99%	80.25%	23.40%	9.49%	39.05%	21.47%	-44.14%	71.51%	165.42%	-220.06%
EPS Q/Q Growth	9.52%	-297.99%	80.25%	39.47%	10.87%	35.37%	26.42%	-41.03%	71.82%	164.52%	-215.00%
Operating Cash Flow Q/Q Growth	-4.39%	26.83%	14.07%	3.71%	22.94%	27.58%	45.03%	72.55%	2.44%	27.58%	419.89%
Free Cash Flow Firm Q/Q Growth	-148.36%	24.86%	66.14%	225.67%	12.22%	-117.45%	5.04%	105.67%	110.31%	35.74%	-182.90%
Invested Capital Q/Q Growth	3.87%	-55.74%	-5.85%	13.49%	0.21%	1.71%	-2.28%	-4.07%	0.15%	8.21%	-3.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	16.28%	-26.61%	35.32%	38.51%	47.39%	53.56%	59.93%	60.91%	62.22%	69.22%	67.13%
EBITDA Margin	-80.74%	-448.19%	-121.62%	-77.31%	-65.36%	-35.32%	-23.19%	-32.97%	-2.06%	12.20%	0.27%
Operating Margin	-109.11%	-529.56%	-139.93%	-105.99%	-80.61%	-44.66%	-21.88%	-15.00%	-10.12%	9.21%	-5.22%
EBIT Margin	-93.51%	-503.67%	-141.64%	-98.53%	-81.63%	-45.94%	-31.60%	-40.37%	-9.78%	6.39%	-6.25%
Profit (Net Income) Margin	-93.21%	-503.28%	-141.38%	-95.92%	-79.33%	-44.89%	-32.42%	-41.37%	-10.81%	5.69%	-7.49%
Tax Burden Percent	99.92%	100.03%	99.76%	99.58%	99.59%	98.43%	99.60%	99.35%	99.44%	100.44%	107.35%
Interest Burden Percent	99.76%	99.89%	100.06%	97.76%	97.58%	99.27%	103.03%	103.14%	111.22%	88.58%	111.76%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.44%	0.00%
Return on Invested Capital (ROIC)	-91.97%	-894.27%	-163.98%	-55.17%	-35.70%	-30.93%	-17.29%	-12.49%	-9.23%	13.13%	-5.77%
ROIC Less NNEP Spread (ROIC-NNEP)	-87.04%	-857.89%	-154.38%	-48.05%	-20.69%	-9.25%	-2.30%	41.55%	2.61%	29.02%	8.76%
Return on Net Nonoperating Assets (RNNOA)	51.96%	597.82%	91.61%	15.32%	4.13%	1.39%	0.61%	-6.83%	-0.28%	-2.63%	-0.87%
Return on Equity (ROE)	-40.01%	-296.45%	-72.36%	-39.85%	-31.57%	-29.54%	-16.67%	-19.32%	-9.50%	10.50%	-6.64%
Cash Return on Invested Capital (CROIC)	0.00%	-339.15%	-410.30%	-47.93%	-31.51%	-70.26%	-59.91%	-27.19%	-15.06%	-9.13%	-5.35%
Operating Return on Assets (OROA)	-30.18%	-226.23%	-59.67%	-33.05%	-27.05%	-20.46%	-14.92%	-22.73%	-6.33%	4.66%	-4.90%
Return on Assets (ROA)	-30.08%	-226.05%	-59.56%	-32.18%	-26.29%	-19.99%	-15.31%	-23.29%	-7.00%	4.14%	-5.88%
Return on Common Equity (ROCE)	-40.01%	-296.45%	-72.36%	-39.85%	-31.57%	-29.54%	-16.67%	-19.32%	-9.50%	10.50%	-6.64%
Return on Equity Simple (ROE_SIMPLE)	-49.96%	0.00%	-162.29%	-166.85%	-180.43%	0.00%	-65.16%	-60.54%	-40.83%	0.00%	-14.99%
Net Operating Profit after Tax (NOPAT)	-64	-227	-42	-36	-30	-18	-9.56	-7.41	-5.45	8.85	-3.19
NOPAT Margin	-76.38%	-370.69%	-97.95%	-74.19%	-56.43%	-31.26%	-15.32%	-10.50%	-7.08%	9.25%	-3.66%
Net Nonoperating Expense Percent (NNEP)	-4.93%	-36.38%	-9.60%	-7.12%	-15.01%	-21.67%	-14.99%	-54.04%	-11.84%	-15.89%	-14.52%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-5.22%	-	-	-	2.47%	-0.86%
Cost of Revenue to Revenue	83.72%	126.61%	64.68%	61.49%	52.61%	46.44%	40.07%	39.09%	37.78%	30.78%	32.87%
SG&A Expenses to Revenue	66.00%	70.43%	101.27%	76.67%	48.96%	46.37%	35.96%	35.70%	34.01%	28.60%	36.89%
R&D to Revenue	16.04%	39.72%	33.83%	35.19%	26.81%	21.33%	18.53%	15.46%	15.17%	12.12%	14.44%
Operating Expenses to Revenue	125.39%	502.94%	175.25%	144.50%	128.00%	98.22%	81.82%	75.92%	72.34%	60.02%	72.35%
Earnings before Interest and Taxes (EBIT)	-78	-309	-61	-48	-44	-26	-20	-28	-7.52	6.11	-5.44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-67	-275	-52	-38	-35	-20	-14	-23	-1.59	12	0.24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.60	0.40	0.89	0.52	0.37	0.31	1.14	3.52	5.59	8.61	9.66
Price to Tangible Book Value (P/TBV)	1.76	1.52	2.00	1.31	1.20	1.29	6.20	24.04	26.96	24.37	24.30
Price to Revenue (P/Rev)	1.45	0.43	1.30	0.65	0.45	0.35	1.07	2.80	4.28	6.91	7.53
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.49	0.23	0.80	0.31	0.24	0.27	1.14	3.44	5.68	9.60	11.61
Enterprise Value to Revenue (EV/Rev)	0.93	0.19	0.66	0.28	0.24	0.28	1.07	2.83	4.26	6.82	7.39
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.13	0.26	0.21	0.24	0.28	0.51	0.55	0.58	0.55	0.46	0.43
Long-Term Debt to Equity	0.13	0.26	0.21	0.24	0.28	0.51	0.55	0.58	0.55	0.46	0.43
Financial Leverage	-0.60	-0.70	-0.59	-0.32	-0.20	-0.15	-0.27	-0.16	-0.11	-0.09	-0.10
Leverage Ratio	1.50	1.63	1.62	1.51	1.53	1.89	1.75	1.77	1.80	1.77	1.81
Compound Leverage Factor	1.50	1.63	1.62	1.48	1.49	1.87	1.81	1.82	2.00	1.57	2.02
Debt to Total Capital	11.51%	20.71%	17.59%	19.12%	21.57%	33.65%	35.55%	36.79%	35.47%	31.51%	30.26%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	11.51%	20.71%	17.59%	19.12%	21.57%	33.65%	35.55%	36.79%	35.47%	31.51%	30.26%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	88.49%	79.29%	82.41%	80.88%	78.43%	66.35%	64.45%	63.21%	64.53%	68.49%	69.74%
Debt to EBITDA	-0.25	-0.12	-0.13	-0.16	-0.17	-0.80	-1.08	-1.23	-1.92	-4.08	-8.64
Net Debt to EBITDA	0.40	0.11	0.28	0.20	0.11	0.10	-0.01	-0.07	0.07	1.03	3.67
Long-Term Debt to EBITDA	-0.25	-0.12	-0.13	-0.16	-0.17	-0.80	-1.08	-1.23	-1.92	-4.08	-8.64
Debt to NOPAT	-0.23	-0.14	-0.16	-0.19	-0.21	-0.91	-1.22	-1.74	-2.78	-6.94	-11.32
Net Debt to NOPAT	0.37	0.12	0.32	0.23	0.13	0.11	-0.02	-0.09	0.10	1.74	4.81
Long-Term Debt to NOPAT	-0.23	-0.14	-0.16	-0.19	-0.21	-0.91	-1.22	-1.74	-2.78	-6.94	-11.32
Altman Z-Score	-0.45	-4.38	-1.86	-2.62	-3.48	-3.49	-3.19	-2.08	-0.38	3.95	4.75
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.89	1.47	2.29	2.53	2.51	3.10	3.22	2.38	2.41	3.61	3.25
Quick Ratio	1.45	1.16	1.98	2.26	2.15	2.77	2.80	1.95	2.00	3.26	2.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-566	-425	-144	181	203	-35	-34	1.91	4.01	5.45	-4.51
Operating Cash Flow to CapEx	-2,065.50%	-2,278.15%	-12,025.97%	-1,937.74%	0.00%	-1,339.52%	-3,704.97%	-333.21%	-680.34%	-104.36%	166.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-4,111.37	0.00	0.00	0.00	-56.33	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	-1,587.43	0.00	0.00	0.00	-27.49	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-1,600.63	0.00	0.00	0.00	-28.23	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.32	0.45	0.42	0.34	0.33	0.45	0.47	0.56	0.65	0.73	0.79
Accounts Receivable Turnover	7.05	6.71	6.28	5.85	5.42	5.32	7.10	8.11	7.54	8.67	8.81
Inventory Turnover	6.49	11.10	9.91	7.72	6.11	10.03	9.16	9.82	10.76	11.43	9.45
Fixed Asset Turnover	3.19	4.11	4.05	3.56	3.44	4.82	5.49	6.53	7.95	9.35	9.76
Accounts Payable Turnover	3.67	3.96	3.29	2.37	2.56	1.84	2.06	2.01	2.27	3.29	3.09
Days Sales Outstanding (DSO)	51.74	54.36	58.13	62.38	67.41	68.61	51.39	45.01	48.41	42.09	41.41
Days Inventory Outstanding (DIO)	56.27	32.89	36.84	47.25	59.72	36.39	39.85	37.18	33.91	31.93	38.63
Days Payable Outstanding (DPO)	99.49	92.28	110.79	153.85	142.35	198.35	177.42	181.56	160.60	110.93	118.19
Cash Conversion Cycle (CCC)	8.52	-5.03	-15.82	-44.22	-15.23	-93.35	-86.17	-99.37	-78.28	-36.91	-38.15
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	443	196	185	209	210	213	209	200	200	217	210
Invested Capital Turnover	1.20	2.41	1.67	0.74	0.63	0.99	1.13	1.19	1.30	1.42	1.58
Increase / (Decrease) in Invested Capital	502	198	102	-217	-233	17	24	-9.31	-9.46	3.40	1.33
Enterprise Value (EV)	216	44	147	66	49	57	238	689	1,139	2,083	2,438
Market Capitalization	334	102	291	153	94	71	236	683	1,143	2,111	2,486
Book Value per Share	$1.47	$0.66	$0.41	$11.57	$9.87	$8.81	$7.95	$7.42	$7.59	$8.93	$9.17
Tangible Book Value per Share	$0.50	$0.17	$0.18	$4.55	$3.03	$2.14	$1.46	$1.09	$1.57	$3.15	$3.65
Total Capital	634	320	399	366	324	344	322	307	317	358	369
Total Debt	73	66	70	70	70	116	114	113	112	113	112
Total Long-Term Debt	73	66	70	70	70	116	114	113	112	113	112
Net Debt	-118	-58	-144	-87	-44	-15	1.41	6.10	-4.06	-28	-47
Capital Expenditures (CapEx)	4.28	2.84	0.46	2.76	-0.14	2.23	0.44	1.35	0.65	3.05	6.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-47	-56	-61	-28	-11	-6.63	-0.22	-13	-7.79	1.97	-2.89
Debt-free Net Working Capital (DFNWC)	144	68	153	129	103	124	113	94	109	143	156
Net Working Capital (NWC)	144	68	153	129	103	124	113	94	109	143	156
Net Nonoperating Expense (NNE)	14	81	19	11	12	7.82	11	22	2.87	3.41	3.34
Net Nonoperating Obligations (NNO)	-118	-58	-144	-87	-44	-15	1.41	6.10	-4.06	-28	-47
Total Depreciation and Amortization (D&A)	11	34	8.64	10	8.67	6.09	5.25	5.22	5.93	5.56	5.68
Debt-free, Cash-free Net Working Capital to Revenue	-20.37%	-23.69%	-27.12%	-11.74%	-5.25%	-3.27%	-0.10%	-5.32%	-2.92%	0.64%	-0.87%
Debt-free Net Working Capital to Revenue	62.42%	29.11%	68.48%	54.52%	50.10%	60.98%	50.80%	38.54%	40.66%	46.87%	47.34%
Net Working Capital to Revenue	62.42%	29.11%	68.48%	54.52%	50.10%	60.98%	50.80%	38.54%	40.66%	46.87%	47.34%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.60)	($995.28)	($3.04)	($1.84)	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)
Adjusted Weighted Average Basic Shares Outstanding	11.54M	310.21K	20.06M	25.42M	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M
Adjusted Diluted Earnings per Share	($6.60)	($995.28)	($3.04)	($1.84)	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)
Adjusted Weighted Average Diluted Shares Outstanding	11.54M	310.21K	20.06M	25.42M	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	($995.28)	$0.00	$0.00	$0.00	($1.06)	$0.00	$0.00	$0.00	$0.20	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	11.72M	24.19M	25.59M	25.77M	25.88M	26.05M	26.14M	26.94M	27.47M	28.07M	28.53M
Normalized Net Operating Profit after Tax (NOPAT)	-64	-80	-41	-36	-24	-18	-9.56	-7.41	-5.45	6.16	-3.19
Normalized NOPAT Margin	-76.38%	-130.91%	-94.51%	-74.19%	-45.55%	-31.26%	-15.32%	-10.50%	-7.08%	6.45%	-3.66%
Pre Tax Income Margin	-93.29%	-503.13%	-141.72%	-96.32%	-79.65%	-45.60%	-32.55%	-41.64%	-10.87%	5.66%	-6.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-1,745.74	0.00	0.00	0.00	-33.04	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	-1,207.28	0.00	0.00	0.00	-16.02	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	-1,758.94	0.00	0.00	0.00	-33.78	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	-1,220.48	0.00	0.00	0.00	-16.76	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

GeneDx Holdings Corp. (NASDAQ: WGS) has shown significant financial volatility over the past four years, with key trends in revenue growth, profitability, cash flow, and balance sheet strength noted from quarterly financial statements through Q1 2025.

Operating revenue increased substantially from $43.1 million in Q1 2023 to $87.1 million in Q1 2025, indicating strong top-line growth over two years.
Gross profit improved from $15.2 million in Q1 2023 to $58.5 million in Q1 2025, showing improved operational efficiency despite higher revenues.
Net cash from operating activities turned positive at $10.2 million in Q1 2025 after multiple quarters of negative operating cash flow, signaling potential operational turnaround.
The company raised significant cash via issuance of common equity, including $13.9 million in Q1 2025 and earlier large raises, bolstering liquidity.
Cash and equivalents increased to nearly $100 million in Q1 2025 from $20.1 million at Q1 2023, enhancing financial stability.
Total assets grew from about $545 million in Q1 2023 to $446 million in Q1 2025, with intangibles remaining a large portion, reflecting investment in intellectual property and possibly acquisitions.
Capital lease obligations and long-term debt remain substantial liabilities (~$117 million combined as of Q1 2025), representing ongoing fixed financial commitments.
Net losses persist through Q1 2025, with a loss of $6.5 million in the latest quarter. The company has yet to achieve consistent profitability despite revenue growth.
Operating expenses remain high at $63 million in Q1 2025 relative to revenue, with notable expenditures in marketing ($18.3 million) and R&D ($12.6 million), pressuring margins.
Income tax refunds (negative income tax expense) in recent quarters mask ongoing operating losses, indicating limited current profitability and potential tax headwinds.

Summary: GeneDx has successfully grown revenues and gross profit significantly over the last two years, supported by strategic equity raises that have improved cash reserves and operational cash flow. However, the company still faces challenges with sustained net losses and high operating expenses limiting profitability. The balance sheet shows heavy intangible assets and ongoing lease and debt obligations. Investors should watch for continued improvement in profitability metrics and cash flow stability to confirm durable financial health alongside top-line growth.

08/29/25 05:51 PM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About GeneDx's Financials

When does GeneDx's fiscal year end?

According to the most recent income statement we have on file, GeneDx's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has GeneDx's net income changed over the last 5 years?

GeneDx's net income appears to be on an upward trend, with a most recent value of -$52.29 million in 2024, rising from -$29.70 million in 2019. The previous period was -$175.77 million in 2023.

What is GeneDx's operating income?

GeneDx's total operating income in 2024 was -$23.21 million, based on the following breakdown:

Total Gross Profit: $194.40 million
Total Operating Expenses: $217.61 million

How has GeneDx's revenue changed over the last 5 years?

Over the last 5 years, GeneDx's total revenue changed from $196.17 million in 2019 to $305.45 million in 2024, a change of 55.7%.

How much debt does GeneDx have?

GeneDx's total liabilities were at $174.13 million at the end of 2024, a 8.7% decrease from 2023, and a 29.6% decrease since 2020.

How much cash does GeneDx have?

In the past 4 years, GeneDx's cash and equivalents has ranged from $85.21 million in 2024 to $400.57 million in 2021, and is currently $85.21 million as of their latest financial filing in 2024.

How has GeneDx's book value per share changed over the last 5 years?

Over the last 5 years, GeneDx's book value per share changed from 0.00 in 2019 to 8.93 in 2024, a change of 892.7%.

Related Companies

This page (NASDAQ:WGSWW) was last updated on 8/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGSWW) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About GeneDx's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeneDx (WGSWW) Financials

Annual Income Statements for GeneDx

Quarterly Income Statements for GeneDx

Annual Cash Flow Statements for GeneDx

Quarterly Cash Flow Statements for GeneDx

Annual Balance Sheets for GeneDx

Quarterly Balance Sheets for GeneDx

Annual Metrics And Ratios for GeneDx

Quarterly Metrics And Ratios for GeneDx

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About GeneDx's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools